EBIT at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's EBIT?
- Avalo Therapeutics (AVTX) reported EBIT of -$20.9M in Q1 2026.
- How has Avalo Therapeutics's EBIT changed year-over-year?
- Avalo Therapeutics's EBIT decreased by 42.5% year-over-year, from -$14.67M to -$20.9M.
- What is the long-term trend for Avalo Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Avalo Therapeutics's EBIT has grown at a -2.9% compound annual growth rate (CAGR), from -$82.14M to -$72.93M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.